Are there any issues or interactions when using lamotrigine (Lamictal) together with cyclobenzaprine (Flexeril)?

No Significant Drug-Drug Interaction Between Lamictal and Flexeril

There is no documented pharmacokinetic or pharmacodynamic drug-drug interaction between lamotrigine (Lamictal) and cyclobenzaprine (Flexeril), but caution is warranted due to one case report of severe cutaneous reaction and general concerns about CNS depression and anticholinergic effects in older adults.

Key Safety Considerations

Documented Case Report

A single case report from 2012 describes Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome) apparently precipitated by the combined use of lamotrigine and cyclobenzaprine 1. While this represents only one documented case, it suggests potential for additive risk of serious cutaneous reactions when these medications are combined.

Additive CNS Depression Risk

Both medications can cause central nervous system depression:

• Lamotrigine causes dizziness, somnolence, and other CNS depressant effects 2
• Cyclobenzaprine (a muscle relaxant) has anticholinergic properties and causes sedation 3

The 2019 AGS Beers Criteria specifically warns against concurrent use of three or more CNS agents (including antiepileptics like lamotrigine and muscle relaxants like cyclobenzaprine) due to increased fall risk 4. This is particularly important in older adults.

Special Concerns in Older Adults

Cyclobenzaprine is listed as a potentially inappropriate medication in older adults due to:

• Broad muscarinic receptor blockade
• CNS impairment including delirium and slowed comprehension
• Sedation and increased fall risk
• Impaired vision, urinary retention, and constipation 3

Clinical Recommendations

If both medications must be used together:

1. Monitor closely for cutaneous reactions in the first 8 weeks, particularly:

   • Any new rash or skin changes
   • Fever, lymphadenopathy, or systemic symptoms
   • Signs of erythema multiforme or DRESS syndrome

2. Assess and mitigate fall risk, especially in:

   • Older adults (≥65 years)
   • Patients on multiple CNS-active medications
   • Those with baseline mobility impairment

3. Counsel patients to:

   • Avoid driving or operating machinery until they know how the combination affects them
   • Report any skin changes immediately
   • Be aware of increased sedation risk

4. Consider alternatives to cyclobenzaprine in older adults, as it is on the Beers Criteria list of medications to avoid 3, 4

Common Pitfalls to Avoid

• Don't dismiss new rashes as benign - lamotrigine carries risk of serious cutaneous reactions, and the case report suggests cyclobenzaprine may increase this risk 1
• Don't overlook polypharmacy concerns - if the patient is on other CNS depressants (benzodiazepines, opioids, other antiepileptics), the cumulative risk increases substantially 4
• Don't forget anticholinergic burden - cyclobenzaprine adds to total anticholinergic load, which can cause cognitive impairment, especially in older adults 3